Insider Selling: Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Sells $871,000.00 in Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulse Biosciences Stock Performance

PLSE stock opened at $17.98 on Monday. The business has a fifty day simple moving average of $17.91 and a 200-day simple moving average of $16.64. Pulse Biosciences, Inc. has a 52 week low of $6.59 and a 52 week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the prior year, the business posted ($0.19) earnings per share.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares during the period. State Street Corp lifted its holdings in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pulse Biosciences during the 3rd quarter worth $588,000. Geode Capital Management LLC increased its holdings in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Finally, Barclays PLC raised its position in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.